The metabolic syndrome (MetS) is highly prevalent and associated with an increased risk for type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD). Lifestyle recommendations to treat MetS often include the replacement of saturated fats (SFAs) and monosaccharides with unsaturated fat. However, it is unclear whether metabolic parameters will improve more when the saturated fat in American Heart Association (AHA) diets is replaced with higher concentrations of monounsaturated or polyunsaturated fatty acids (MUFA or PUFA).
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BACKGROUND:
The metabolic syndrome (MetS) is highly prevalent and associated with an increased risk for type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD). Lifestyle recommendations to treat MetS often include the replacement of saturated fats (SFAs) and monosaccharides with unsaturated fat. However, it is unclear whether metabolic parameters will improve more when the saturated fat in American Heart Association (AHA) diets is replaced with higher concentrations of monounsaturated or polyunsaturated fatty acids (MUFA or PUFA).
OBJECTIVE: To test the hypothesis that an AHA diet enriched in MUFA improves lipoprotein lipids, insulin resistance, inflammation, and endothelial function to a greater extent than a diet enriched in PUFA in middle-aged men and women with MetS.
METHODS:
A prospective, open-label, parallel group design with randomization to a hypocaloric MUFA or PUFA-enriched diet after weight stabilization on an AHA step I diet. Participants consumed 3 MUFA-enriched or PUFA-enriched muffins daily with additional supplementation as required to ensure 25%-50% increases in dietary fat intake from these sources at the expense of SFA and the opposing unsaturated fat. Changes in MetS components were measured at baseline and after 6 months of dietary intervention.
RESULTS: Thirty-nine participants (mean age, 60.8 years; 79% African-American, 60% women) with MetS completed the 6-month study. Compared to baseline, assignment to either MUFA (n 5 23) or PUFA (n 5 16) both were associated with weight loss (MUFA: 22.3 6 1 kg, P 5 .06; PUFA: 24.6 6 2 kg; P 5 .002), but PUFA was also associated with reductions in triglycerides
Introduction
The metabolic syndrome (MetS) is a common condition characterized by 3 or more of the following metabolic abnormalities 1 : BP $130/85 mm Hg, 2 fasting glucose $100 mg/dL, 3 waist circumference $ 102 cm (40 inches) in men and 88 cm (35 inches) in women and dyslipidemia 4 (triglycerides [TG] $150 mg/dL and 5 high-density lipoprotein cholesterol [HDL-C] ,40 in men and ,50 mg/dL in women). The metabolic syndrome is associated with an increased risk of type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD).
1,2 Although lifestyle modification (changes in diet and increased activity) is the cornerstone of initial therapy in MetS, the most beneficial dietary measures to reduce weight and improve the associated abnormal metabolic characteristics of the MetS remain unclear. After early studies identified a high intake of saturated animalbased fat to be associated with increased risk of CVD, 3-7 a shift to higher carbohydrate (CHO) combined with lower total and saturated fat acid (SFA) intake was advocated by the American Heart Association (AHA). 8 However, because high CHO diets enriched with monosaccharides were associated with worsening of metabolic parameters, especially in subjects with obesity and T2DM, the scientific sentiment shifted in favor of substitution of unsaturated fat. 9 Unsaturated fats are divided into two types, monounsaturated and polyunsaturated fats. However, the optimum type of fat to consume remains controversial. For example, higher intake of monounsaturated fatty acids (MUFAs) has been associated with reduced CVD risk in some studies, 10, 11 whereas other studies identified polyunsaturated fatty acids (PUFAs) to be more strongly cardioprotective. 12, 13 Intake of MUFA or PUFA has been shown to reduce inflammation, 14, 15 although it is suggested that MUFA may be more potent than PUFA at reducing oxidation of LDL particles 16 and decreasing platelet aggregation. 17 Moreover, a MUFA-enriched Mediterranean diet is associated with reduced incidence of MetS and components of MetS, 18 as well as excellent adherence rates. 19 Thus, a MUFA-enriched diet may be the most acceptable diet for MetS, from both a biochemical and adherence standpoint. Yet, few if any studies have directly compared a hypocaloric AHA diet enriched in MUFA or PUFA and lower in SFA on the metabolic abnormalities associated with MetS. This is an important clinical issue because long-term improvement in these metabolic parameters might translate into reduced risk of CVD complications associated with MetS. We hypothesized that a MUFA rather than a PUFAenriched AHA diet combined with weight loss would be associated with greater cardiometabolic benefits of MUFA as compared to PUFA in overweight subjects with MetS.
Materials and methods
Adult men and women with MetS were recruited from the Baltimore VA Medical Center, University of Maryland Medical Center and local hospital outpatient general medicine clinics. Inclusion criteria permitted the use of medication for hypertension and type 2 diabetes mellitus (T2DM) (e.g., oral hypoglycemic agents) provided that the medication dosage regimen was stable for a minimum of 3 months before study entry. Exclusion criteria included subjects with T2DM treated with insulin, hemoglobin A1C .9% or untreated metabolic (e.g., thyroid, Cushing's) disorders. The study was designed to measure several different cardiovascular (CV) risk-associated parameters including (1) biochemical measurements (e.g., lipoprotein lipids, glucose, insulin, biomarkers of inflammation), and (2) physiological assessment of endothelial function using brachial artery reactivity testing (BART).
20 Figure 1 provides an overview of the study design. All subjects were instructed and weight stabilized on an AHA Step 1 diet 1 for 1-2 months, after, which baseline (time 0) measurements of body weight, waist circumference, resting BP, fasting lipids, glucose, and inflammatory proteins were measured after a 12-hour overnight fast as previously described. 13, 21 On separate days after a 12-hour overnight fast, BART was performed to measure flow-mediated dilation (FMD). 21 All subjects signed informed consent, and the protocol was approved by the Institutional Review Boards of the University of Maryland School of Medicine and the Baltimore Veterans Affairs Medical Center.
Dietary instruction and randomization to higholeic sunflower or safflower oil based muffins During the AHA step 1 stabilization diet and at baseline, energy intake was composed of 45%-50% carbohydrates, 15%-20% protein and 30%-35% of fat divided approximately equally between SFA, MUFA, and PUFA. After baseline measurements, subjects were randomized using a 1:1 assignment ratio to either a hypocaloric MUFA-enriched or PUFA-enriched diet for 6 months aimed at reducing energy intake by w300 kcal/day. Although the relative percentages of CHO, fat, and protein were kept constant, the SFA content was reduced in both groups from w30% to w25% of total fat intake and replaced with either MUFA or PUFA. Dietary assignment included daily consumption of 3 MUFA (high-oleic sunflower oil) or PUFA (safflower oil) enriched muffins. Each 3.5-ounce muffin contained 275 calories; high-oleic sunflower oil muffins contained 10.3-g MUFA, 0.7-g PUFA, and 1.4-g SFA and safflower oil muffins contained 9.2-g PUFA, 2-g MUFA, and 1-g SFA. All muffins were prepared in the metabolic kitchen of the USDA (Beltsville, MD) and kept frozen in a canister until use. Participants met with a registered dietitian weekly for the first 4 months and then biweekly to collect a fresh supply of muffins and reinforce individual dietary and weight loss recommendations. Participants were also asked to complete 7-day food records on completion of baseline testing (immediately before the MUFA-PUFA intervention) and at the end of the 6-month MUFA-PUFA intervention. The dietary food records included the number of muffins consumed daily as well as consumption of other MUFA and PUFA containing foods. Energy and nutrient composition was assessed using Nutritionist Pro software.
MOVE! program
At baseline, participants received a submaximal Bruce exercise stress test 22 was performed to evaluate cardiovascular safety for exercise and endurance, after, which they were instructed by an exercise physiologist on the Veteran's Affairs-based MOVE! program. The MOVE! program is a leisurely home-based walking program. 23 During the 6-month intervention phase, subjects were encouraged to walk on their own at least 3 days per week for 30-45 minutes. After completion of the 6-month MUFA or PUFA assignment, subjects were weight stabilized for 10 days before repeat post-dietary testing.
Lipoprotein and biochemical analysis
After an overnight fast, 30 mL of blood was collected by venipuncture into 2 tubes containing EDTA and centrifuged within 30 minutes at 4 C to separate plasma. Total cholesterol and TG concentrations were measured using a Hitachi 704 clinical chemistry analyzer (Boehringer Mannheim Diagnostics, Indianapolis, IN) with reagents supplied by the manufacturer (cholesterol/HP, cat. no. 816302; triglycerides/GPO, cat. no 816370). HDL-C was measured in the clear supernatant after a double precipitation with highmolecular weight dextran sulfate as previously described. 24 Plasma samples were stored at 280 C for analysis of inflammatory biomarkers high-sensitivity C-reactive protein (hs-CRP), interleukin-8 (IL-8), and tumor necrosis factor alpha (TNFa) using a Proinflammatory Panel V-Plex Kit (Meso Scale Diagnostics, Inc). Glucose levels were measured by a glucose oxidase method (Beckman Instruments, Fullerton, CA) and insulin by insulin specific double antibody radioimmunoassay using human insulin standards and tracer (Linco, St. Louis, MO) with baseline and postintervention samples included in the same assay.
FMD assessment
Subjects were instructed to be in a fasting state and not smoke or drink coffee for 12 or more hours before the study. The next morning, they were positioned on a stretcher bed in a temperature-controlled room designated for BART studies to measure FMD. An automatic blood pressure cuff was placed on the right arm for intermittent blood pressure and heart rate monitoring throughout the study. Electrodes were placed to monitor a one-lead EKG from the ultrasound system. Another blood pressure cuff was placed on the subject's upper left arm well above the antecubital fossa. The brachial artery was imaged above the antecubital fossa in the longitudinal plane by continuous 2D gray-scale imaging using an 11-MHz ultrasound (HDI 5000 [Phillips, Andover, Massachusetts]) by a trained sonographer as previously described. 21 The blood pressure cuff was inflated to 200 mm Hg and kept inflated for 5 minutes. On immediate release of the cuff, the brachial artery was imaged, and Doppler assessment of the hyperemic velocity was recorded within 8 seconds followed by 2D imaging with maximum dilation occurring 1 minute after cuff release. Using longitudinal images, the boundaries for diameter measurement were calibrated manually at the lumen-intima interface. All images were captured on videotape and read in a blinded fashion.
Statistical analyses
Baseline (after the baseline AHA diet and immediately before MUFA or PUFA assignment) comparisons of subjects randomized to MUFA vs. PUFA groups was performed with one-way ANOVA. The group changes (6-month value minus baseline) were computed and compared between groups using one-way ANOVA adjusted for the baseline value of the outcome measure and the change in weight that occurred during the 6-month MUFA-PUFA intervention (change 5 group 1 baseline value 1 weight change). Results are presented as mean 6 SEM. A twotailed P , .05 was considered statistically significant. Statistical analyses were performed using SAS software, version 9.4 (SAS Institute, Cary, NC).
Results
Subjects
A total of 182 men and women were screened for the study and of the 60% who qualified (n 5 110) 20% dropped out during the AHA dietary baseline phase (n 5 88) and 44% (n 5 39) completed the 6-month dietary MUFA (n 5 23) or PUFA (n 5 16) intervention. The postrandomization attrition rate included unanticipated medical and family events (e.g., extended medical illness) and loss to follow-up. The study subjects, 60% were women and 79% were African-American were obese (mean body mass index, 35.7 6 0.9 kg/m 2 ; range, 22-47 kg/m 2 ) with a mean age of 60.9 6 8.5 years (range, 38-76) for whom. Of medications affecting BART, only a small percentage received statins (MUFA, 26%; PUFA, 25%) or angiotensinconverting enzyme inhibitors (MUFA, 26%; PUFA, 19%) at baseline. Medications and dosage regimen remained stable throughout the 6-month study.
Dietary compliance
As shown in Table 1 , 34 of 39 participants completed 7-day dietary food records, providing the energy and macronutrient composition at baseline (time 0) and at completion of the 6-month MUFA or PUFA dietary intervention There were no significant differences between the 2 groups in total energy intake or in CHO, protein, total, or saturated fat at baseline. Similarly, the change in these metabolic components over the 6-month intervention did not differ between groups. During the study, the proportion of SFA to total fat consumed was reduced in MUFA (29% to 26%; P 5 .08) and PUFA assigned groups (28% to 25%; P , .01). Reciprocally, there was a 46% increase in the MUFA/SFA ratio in the MUFA group (P , .0001), whereas assignment to PUFA was associated with a 59% increase in PUFA/SFA intake (P , .005). Not surprisingly, assignment to MUFA resulted in increased consumption of 18:1 oleate (P , .01), whereas PUFA treatment was associated with greater intake of 18:2 linoleate (P , .01) and a-tocopherol (P , .0001). Because omega-3 fish oil capsule supplementation was not permitted by the subjects, there were no significant differences in the intake of marine-based 20:5 EPA (eicosapentanoic acid) and 22:6 DHA (docosahexanoic acid) between the groups.
Cardiometabolic outcomes
The prevalence of MetS components at baseline was hypertension (90%), fasting plasma glucose $ 100 mg/dL (82%) or T2DM (51%), increased waist circumference (72%), low HDL-C (67%), and TG . 150 mg/dL (21%). Compared to baseline, reductions in body weight and waist circumference were observed after MUFA (22.3 6 1 kg, P 5 .06: 22.8 6 1 cm, P 5 .02) and PUFA (24.6 6 2 kg, P 5 .002: 25.8 6 2 cm, P 5 .001) intervention. The MUFA group demonstrated borderline significant decreases in insulin (P 5 .06) and HOMA-IR, whereas PUFA intervention was also associated with significant reductions in TG (230 6 18 mg/dL, P 5 .02), systolic blood pressure (BP) (27 6 3 mm Hg, P 5 .01), diastolic BP (DBP) (24 6 2 mm Hg, P 5 .01) and improved FMD (regardless of whether the change was expressed in mm or as a percentage change; Table 2 ).
Analysis of covariance demonstrated that the beneficial effects of PUFA compared to the MUFA-enriched diet on TG (P 5 .04), FMD (P 5 .04), and DBP (P 5 .07) persisted independent of weight loss. However, the effects of both diets on biomarkers of inflammation (hs-CRP, IL-8, and TNFa) were highly variable, and between group differences did not reach statistical significance. Overall, 18% subjects converted from MetS to non-MetS status, but there were no differences in conversion between the PUFA (4 of 16, 25%) and MUFA (3 of 23, 13%) MUFA groups (P , .42, Fisher exact test).
Discussion
Our randomized study in which MUFA-enriched and PUFA-enriched fatty acids were substituted for SFA represents, to our knowledge, the first comparative study demonstrating the statistically significant beneficial effects of PUFA compared to MUFA in treating two components of MetS (weight and TG), a favorable trend on a third component (DBP) and clear benefits to FMD. The positive results in PUFA vs MUFA are contrary to our original hypothesis and the known beneficial effects of MUFAenriched diets on metabolism. 9, 18, 19 It is possible that the addition of weight loss and the VA MOVE! Program in our obese subjects with MetS and T2DM receiving the PUFA diet likely contributed to the favorable outcomes.
Prior studies that focused on strategies for weight loss (w5%-7% of body weight) via diet with or without lowintensity physical activity showed improvements in MetS constituents. 25, 26 Conversely, a diet high in SFA worsens MetS components and is associated with impaired FMD. 21 Although not all SFAs (e.g., plant-based) are highly atherogenic, animal-derived SFAs (i.e., red meat) are associated with a 25% increased risk of CV events. 27 Indeed, with few exceptions, 28 replacement of SFA for unsaturated fat is associated with reduced CV risk. 8 A pooled analysis of 11 cohort studies found a 13% reduced CV risk when PUFA was substituted for SFA. 12 The present study shows that the dietary substitution of SFA with PUFA or MUFA is associated with a 6.5% absolute increase in FMD a magnitude of change that is considered highly significant. 20 Although the present study found MUFA enrichment to be associated with a 13% conversion rate to non-MetS status, PUFA enrichment exhibited a 25% conversion rate, primarily by reducing waist, TG, and a nonstatistically significant trend toward reducing BP. Although not demonstrated in the present study, the anti-inflammatory actions of PUFAs to lower acute phase reactants and proinflammatory mediators, even in the absence of any appreciable intake of marine-derived omega-3 fatty acids are potential mechanisms to reduce CVD risk in MetS and T2DM. 29, 30 The reduction in cytokine release from adipose tissue decreases adipocyte lipolysis and FFA levels 31 and is associated with increased PPARg activity and insulin sensitivity, all of which could reduce TG production 32 in MetS. Nevertheless, these metabolic advantages of PUFA compared to MUFA intake are relatively modest, and to some extent, consistent with weight loss serving as a relevant contributor to the observed metabolic benefits. 33, 34 To exclude the possibility of differences in the palatability and thus differential adherence to the MUFA vs PUFA intervention, we blindly pretested the taste of the muffins at the onset of the trial. In fact, participants reported that they enjoyed consuming the assigned muffins. A potential reason for the greater weight loss in PUFA than in MUFA subjects is suggested by greater increases in the anorexigenic hormone peptide YY after PUFA intake compared to MUFA or SFA. 35 In addition to the 4.6% reduction in body weight, PUFA enrichment continued to be associated with improved FMD, TG, and a trend toward reduced DBP compared to MUFA assignment, even after controlling for weight loss. The basis for these differences is unclear but may in part be related to the relatively low SFA intake (8.8% of total energy), which we previously showed to be inversely related to FMD. 21 Indeed, the magnitude of improvement in FMD after PUFA treatment is similar to previous BART studies evaluating pharmacologic interventions (e.g., statins, ACE-inhibitors), 20, 36 and the recent demonstration of an inverse association between PUFA intake and CVD risk further supports the substitution of a PUFA-enriched diet in place of SFA and trans fats. 37 There are several strengths and limitations associated with our study. Strengths included the use of USDA produced MUFA-enriched and PUFA-enriched muffins. To avoid potential confounding due to initial metabolic state, we designed the study so that subjects were metabolically and weight stabilized on an AHA type-I diet before the MUFA or PUFA intervention. Another notable highlight was the high percentage of African American (79%) participants, a group that is commonly underrepresented in clinical studies. Moreover, the prior studies that included subjects of African descent were generally observational, using food-frequency questionnaires rather than a randomized intervention clinical trial. 38 Unfortunately, the group samples were too small for a racespecific analysis.
Study limitations include the high post-randomization dropout rate of 55%. The value is similar to recent studies, which have had rates of 50%-60% range over a 6-month outpatient nutrition study period. 39, 40 Despite the high dropout rate, there was good compliance across the study groups in meeting the nutritional goals of this clinical trial, as evidenced by the 88% completion rate of food records (i.e., 34 of 39 subjects). Another limitation is the use of food record recall to assess dietary intake, a metric far less sensitive than when all meals are prepared and distributed from a metabolic kitchen. Although all muffins were prepared by the USDA, additional dietary recommendations of required MUFA or PUFA intake were individualized by the dietitian according to participant preferences and standardized between the two groups for intake. Overall, the food records, while variable, met the study requirements and the primary endpoints of the study, both of which were favorably influenced by the PUFA more than MUFA diet. Finally, there were several dropouts who provided blood samples at their 6-month follow-up visit but chose not to return for their follow-up BART study due to logistical reasons (e.g., transportation, scheduling).
Conclusion
The results of this small, randomized clinical trial suggest PUFA rather than MUFA may be the unsaturated fat of choice for caloric replacement of saturated fatty acids in obese middle-aged men and women with MetS who are already after an AHA type-I diet and who are trying to lose weight and improve their cardiovascular risk profile. Although the diets were adhered to and there were no apparent differences in energy intake between groups according to the food records, controlled metabolic dietary studies would be needed in a larger study sample to confirm these preliminary results and determine the mechanisms underlying the observed PUFA-derived cardiometabolic benefits in patients with MetS.
